Ascendis, BioMarin Reach Global YUVIWEL License Deal
COPENHAGEN, Denmark, August 31, 2026 Ascendis Pharma A/S and BioMarin Pharmaceutical Inc. have entered into a binding term sheet...
rare disease
Advertisement
Amarin Highlights New REDUCE-IT Data at ESC 2026
DUBLIN and BRIDGEWATER, N.J., August 31, 2026 Amarin Corporation plc highlighted new findings from multiple REDUCE-IT® analyses presented at...
PharmaEssentia Wins FDA Approval for BESREMi in ET
BURLINGTON, Mass., August 31, 2026 PharmaEssentia announced that the U.S. Food and Drug Administration (FDA) has approved BESREMi® (ropeginterferon...
Acadia Pharmaceuticals’ DAYBU Approved in EU for Rett Syndrome
SAN DIEGO, U.S, Aug 28, 2026 Acadia Pharmaceuticals Inc. announced that the European Commission (EC) has granted marketing authorization...
Takeda Wins Japan Approval for ORZEYFUL in Narcolepsy
OSAKA, Japan & CAMBRIDGE, Massachusetts, Aug 24, 2026 Takeda Pharmaceutical Company Limited announced that Japan’s Ministry of Health, Labour...
Advertisements
Orsini Partners With Priovant to Support LISRAYA Access
ELK GROVE VILLAGE, Illinois, Aug 28, 2026 Orsini announced that it will serve as a specialty pharmacy partner for...
Priovant Wins FDA Approval for Lisraya in Dermatomyositis
SILVER SPRING, MARYLAND, Aug 27, 2026 Priovant Therapeutics Inc. has received U.S. Food and Drug Administration (FDA) approval for...
iECURE Reports 74% Reduction in OTC-HOPE Crises
Philadelphia – August 27, 2026 iECURE, Inc. presented updated clinical data from the ongoing OTC-HOPE Phase 1/2 trial of...
FDA Approves Janssen’s Imaavy for Rare Blood Disorder
SILVER SPRING, MARYLAND, Aug 26, 2026 The U.S. Food and Drug Administration (FDA) has approved Imaavy (nipocalimab-aahu) injection for...
Daiichi Sankyo, AstraZeneca Advance Datroway in Phase 3 Urothelial Cancer Trial
Tokyo, August 26, 2026 Daiichi Sankyo announced that the first patient has been dosed in TROPION-Urothelial04, a global Phase...
Advertisement
